Public Engagement and Clinical Trials New Models and Disruptive Technologies: Workshop Summary (2012) / Chapter Skim
Currently Skimming:
Appendix A: Workshop Agenda
Appendix A: Workshop Agenda
Pages 89-98
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 89... ...
In addition, the divide between clinical research and clinical practice is growing wider -- physicians working in real world clinical care settings are removed from the clinical trials on which medical evidence and care choices are ideally made. Successfully engaging 89
|
From page 90... ...
in the clinical trial enterprise is a significant challenge. In light of these current challenges to clinical trials in the United States, this collaboration between the IOM Forum on Drug Discovery, Development, and Translation and Mount Sinai School of Medicine seeks to engage stakeholders and experts in an open discussion of current challenges and potential solutions to improving the capacity for efficient conduct of clinical trials in the United States through enhancing public engagement.
|
From page 91... ...
91 APPENDIX A 12:00-12:10 PM Welcome Dennis Charney, Dean, Mount Sinai School of Medicine Jeffrey Drazen, Co-Chair, Forum on Drug Discovery, Development and Translation, New England Journal of Medicine 12:10-12:25 PM Shaping an Effective and Efficient Clinical Trial Enterprise: What Are the Challenges? annetine GeliJns anD Deborah asCheim, Mount Sinai School of Medicine 12:25-12:45 PM An Effective Clinical Trial System: A Perspective from the NIH Clinical Center Juan lertora, National Institutes of Health 12:45-1:30 PM Panel Discussion: A Perspective from Industry, Patient Advocates, Payors, and Regulatory Agencies leslie ball, fDa Joan finneGan brooks, Patient-Focused Market Research anGela GeiGer, Alzheimer's Association riCharD murray, Merck GreG simon, Pfizer bruCe VlaDeCk, Nexera SESSION II: MODELS AND METHODS FOR PUBLIC ENGAGEMENT Moderator: Nancy Sung, Burroughs Wellcome Fund Session Objectives: • hrough case examples, discuss various stakeholder perspectives T and efforts focused on public engagement.
|
From page 92... ...
1:35-1:50 PM Recruitment Challenges in Cardiothoracic Surgical Trials robert miChler, Montefiore-Einstein Heart Center 1:50-2:05 PM Diabetes, Clinical Trials, and Innovative Community Partnerships Carol horowitz anD nina biCkell, Mount Sinai School of Medicine 2:05-2:20 PM Clinical Trials in Mental Health wayne GooDman, Mount Sinai School of Medicine 2:20-2:35 PM Recruitment in Breast Cancer Trials, A New Approach: The Love/Avon Army of Women marC hurlbert, Avon Foundation Breast Cancer Crusade 2:35-2:55 PM Panel Discussion kenneth DaVis, The Mount Sinai Medical Center robert miChler, Carol horowitz, nina biCkell, wayne GooDman, marC hurlbert 2:55-3:20 PM COFFEE BREAK
|
From page 93... ...
. 3:25-3:40 PM 23andMe brian nauGhton, Chief Scientist, 23andMe 3:40-3:55 PM Social Networks and Public Engagement in Clinical Trials bernaDette boDen-albala, Columbia University 3:55-4:15 PM Panel Discussion SESSION IV: MEDIA AND PUBLIC ENGAGEMENT IN CLINICAL TRIALS Moderator: Paul Costello, Stanford School of Medicine Session Objectives: • iscuss the role in public engagement of media, health care informa D tion portals, and public advocates.
|
From page 94... ...
• iscuss the ways in which novel clinical trial designs can enhance D public engagement in clinical research and address treatment assign ment concerns of physicians and their patients. 8:05-8:20 AM The Promise of Novel Trial Designs miChael PariDes, Mount Sinai School of Medicine 8:20-8:35 AM Trial Designs Addressing Treatment Assignment Concerns louis fiore, VA Boston Healthcare System 8:35-8:55 AM Perspective of the Food and Drug Administration (FDA)
|
From page 95... ...
9:20-9:35 AM Building a Clinical Trials Culture in Academia eriC rose, Mount Sinai School of Medicine 9:35-9:50 AM Exploring Novel Institutional Models in Cancer GeorGe Demetri, Dana-Farber Cancer Institute and Harvard Medical School 9:50-10:05 AM New Organizational Models in Rheumatoid Arthritis Trials James o'Dell, Rheumatoid Arthritis Investiga tional Network (RAIN) , University of Nebraska 10:05-10:20 AM ResearchMatch.org and Other IT Solutions Paul harris, Vanderbilt University
|
From page 96... ...
• hat are the most pressing structural and cultural needs for a local W health care system to enhance promotion of public and professional engagement and participation in clinical trials? • hat efforts aimed at physicians, researchers, patients, and the W broader public will facilitate closing the gap between clinical research ers and clinical practitioners?
|
From page 97... ...
97 APPENDIX A 12:05-12:15 PM Building a Comprehensive Strategy: A Summary of the Meeting Jeffrey Drazen, New England Journal of Medicine 12:15-12:30 PM Summary Discussion Jeffrey Drazen, New England Journal of Medicine Juan lertora, National Institutes of Health GreG simon, Pfizer nanCy sunG, Burroughs Wellcome Fund 12:30 PM Adjourn
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.